Rhythm Pharma’s obesity drug fails to meet main goal in late-stage trial - Regional Media News

Rhythm’s Imcivree fails Phase III rare disease obesity trial

Rhythm said that the failed trial of Imcrivee suffered a high dropout rate, which impacted the primary endpoints.The post Rhythm’s Imcivree fails Phase III rare disease obesity trial appeared first on Clinical Trials Arena.

Rhythm’s Imcivree fails Phase 3 for rare form of obesity as PDUFA date nears for larger indication

Rhythm Pharmaceuticals’ Imcivree has hit a snag on the way to a major approval deadline. The biotech’s MC4R agonist failed to significantly reduce weight in a Phase 3 trial that enrolled patients with rare, genetically ...

Rhythm Pharma’s obesity drug fails to meet main goal in late-stage trial - Regional Media News

March 16 (Reuters) - Rhythm Pharmaceuticals said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial. Shares of the Boston-based company fell over 7% in extended trading. The trial was testing whether the drug, setmelanotide, could meaningfully reduce body mass index, or BMI, compared to a placebo over 52 weeks in patients whose obesity is caused by specific genetic mu…